Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 7
Submit an article Journal homepage
587
Views
0
CrossRef citations to date
0
Altmetric
Review

SGLT2: A Potential Target for the Pharmacogenetics of Type 2 Diabetes?

Anke Tönjes1 University of Leipzig, Medical Department, Liebigstraße 21, 04103Leipzig, Germany;2 Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, GermanyView further author information
&
Peter Kovacs1 University of Leipzig, Medical Department, Liebigstraße 21, 04103Leipzig, Germany;2 Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, GermanyCorrespondence[email protected]
View further author information
Pages 825-833 | Published online: 08 May 2013

References

  • Shields BM , HicksS, ShepherdMH, ColcloughK, HattersleyAT, EllardS. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia53 , 2504–2508 (2010).
  • Gloyn AL . Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mut.22 , 353–362 (2003).
  • Gloyn AL , EllardS. Defining the genetic aetiology monogenic diabetes can improve treatment. Expert Opin. Pharmacother.7 , 1759–1767 (2006).
  • Fajans SS , BellGI, PolonskyKS. Mechanisms of disease: molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med.345 , 971–980 (2001).
  • Gloyn AL , PearsonER, AntcliffJF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350 , 1838–1849 (2004).
  • Hattersley AT , AshcroftFM. Activating mutations in Kir6.2 and neonatal diabetes – new clinical syndromes, new scientific insights, and new therapy. Diabetes54 , 2503–2513 (2005).
  • Flanagan SE , PatchAM, MackayDJG et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56 , 1930–1937 (2007).
  • Pearson ER , FlechtnerI, NjolstadPR et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355 , 467–477 (2006).
  • Smith RJ , NathanDM, ArslanianSA, GroopL, RizzaRA, RotterJI. Individualizing therapies in Type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J. Clin. Endocrinol. Metab.95 , 1566–1574 (2010).
  • Altshuler D , HirschhornJN, KlannemarkM et al. The common PPAR β Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes. Nat. Genet. 26 , 76–80 (2000).
  • O‘Rahilly S , BarrosoI, WarehamNJ. Genetic factors in Type 2 diabetes: the end of the beginning? Science307 , 370–373 (2005).
  • Grant SF , ThorleifssonG, ReynisdottirI et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet. 38 , 320–323 (2006).
  • Clatworthy JP , SubramanianV. Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies. Mech. Dev.101 , 3–9 (2001).
  • Cauchi S , MeyreD, DinaC et al. Transcription factor TCF7L2 genetic study in the French population – expression in human β-cells and adipose tissue and strong association with Type 2 diabetes. Diabetes 55 , 2903–2908 (2006).
  • Cauchi S , ElAchhabY, ChoquetH et al. TCF7L2 is reproducibly associated with Type 2 diabetes in various ethnic groups: a global meta-analysis. J. Mol. Med. 85 , 777–782 (2007).
  • Damcott CM , PollinTI, ReinhartLJ et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with Type 2 diabetes in the Amish – replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 55 , 2654–2659 (2006).
  • Florez JC , JablonskiKA, BayleyN et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N. Engl. J. Med.355 , 241–250 (2006).
  • Grant SFA , ThorleifssonG, HelgasonA et al. Refinement of the association between the TCF7L2 gene and Type 2 diabetes in a west African population. Diabetologia 49 , 16–17 (2006).
  • Groves CJ , ZegginiE, MintonJ et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a Type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55 , 2640–2644 (2006).
  • Helgason A , PalssonS, ThorleifssonG et al. Refining the impact of TCF7L2 gene variants on Type 2 diabetes and adaptive evolution. Nat. Genet. 39 , 218–225 (2007).
  • Kimber CH , DoneyAS, PearsonER et al. TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia50 , 1186–1191 (2007).
  • Scott LJ , BonnycastleLL, WillerCJ et al. Association of transcription factor 7-like 2 (TCF7L2) variants with Type 2 diabetes in a Finnish sample. Diabetes 55 , 2649–2653 (2006).
  • Wang J , KuusistoJ, VanttinenM et al. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to Type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 50 , 1192–1200 (2007).
  • Zeggini E , McCarthyMI. TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia50 , 1–4 (2007).
  • Zhang C , QiL, HunterDJ et al. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of Type 2 diabetes in large cohorts of U.S. women and men. Diabetes 55 , 2645–2648 (2006).
  • Pearson ER , DonnellyLA, KimberC et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas – a GoDARTs study. Diabetes 56 , 2178–2182 (2007).
  • Holstein A , HahnM, KornerA, StumvollM, KovacsP. TCF7L2 and therapeutic response to sulfonylureas in patients with Type 2 diabetes. BMC Med. Genet.12 , 30 (2011).
  • Zhou K , BellenguezC, SpencerCC et al. Common variants near ATM are associated with glycemic response to metformin in Type 2 diabetes. Nat. Genet. 43 , 117–120 (2011).
  • van Leeuwen N , NijpelsG, BeckerML et al. A gene variant near ATM is significantly associated with metformin treatment response in Type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 55 , 1971–1977 (2012).
  • Nair S , WildingJPH. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab.95 , 34–42 (2010).
  • Lee YJ , LeeYJ, HanHJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int.72 , S27–S35 (2007).
  • Abdul-Ghani MA , DefronzoRA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in Type 2 diabetes mellitus. Endocr. Pract.14 , 782–790 (2008).
  • Wright E , TurkE. The sodium/glucose cotransport family SLC5. Pflugers Arch. Eur. J. Physiol.447 , 510–518 (2004).
  • Wright EM . Renal Na+-glucose cotransporters. Am. J. Physiol. Renal Physiol.280 , F10–F18 (2001).
  • Powell DR , DaCostaCM, GayJ et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metabol. 304(2) , E117–E130 (2012).
  • Kamran M , PetersonRG, DominguezJH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J. Am. Soc. Nephrol.8 , 943–948 (1997).
  • Marks J , CarvouNJC, DebnamES, SraiSK, UnwinRJ. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J. Physiol.553 , 137–145 (2003).
  • Noonan WT , ShapiroVM, BanksRO. Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. Life Sci.68 , 2967–2977 (2001).
  • Freitas HS , AnheGF, MeloKFS et al. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1α expression and activity. Endocrinology 149 , 717–724 (2008).
  • Rahmoune H , ThompsonPW, WardJM, SmithCD, HongG, BrownJ. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes54 , 3427–3434 (2005).
  • Pontoglio M , SreenanS, RoeM et al. Defective insulin secretion in hepatocyte nuclear factor 1α-deficient mice. J. Clin. Invest. 101 , 2215–2222 (1998).
  • Pontoglio M , PrieD, CheretC et al. HNF1 α controls renal glucose reabsorption in mouse and man. EMBO Rep. 1 , 359–365 (2000).
  • Pontoglio M , BarraJ, HadchouelM et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal fanconi syndrome. Cell 84 , 575–585 (1996).
  • Menzel R , KaisakiPJ, RjasanowskiI, HeinkeP, KernerW, MenzelS. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1α (HNF-1α) gene. Diab. Med.15 , 816–820 (1998).
  • Schiffer M , SusztakK, RanallettaM, RaffAC, BöttingerEP, CharronMJ. Localization of the GLUT8 glucose transporter in murine kidney and regulation in vivo in nondiabetic and diabetic conditions. Am. J. Physiol. Renal Physiol.289 , F186–F193 (2005).
  • Doege H , SchürmannA, BahrenbergG, BrauersA, JoostHG. GLUT8, a novel member of the sugar transport facilitator family with glucose transport activity. J. Biol. Chem.275 , 16275–16280 (2000).
  • Gorboulev V , SchürmannA, VallonV et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61 , 187–196 (2012).
  • Calado J , LoefflerJ, SakalliogluO et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 69 , 852–855 (2006).
  • Calado J , SznajerY, MetzgerD et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol. Dial. Transplant. 23 , 3874–3879 (2008).
  • Santer R , KinnerM, LassenCL et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J. Am. Soc. Nephrol. 14 , 2873–2882 (2003).
  • Yu L , LvJC, ZhouXJ, ZhuL, HouP, ZhangH. Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum. Genet.129 , 335–344 (2011).
  • Santer R , CaladoJ. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol.5 , 133–141 (2010).
  • Katsuno K , FujimoriY, TakemuraY et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320 , 323–330 (2007).
  • Fujimori Y , KatsunoK, OjimaK et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur. J. Pharmacol. 609 , 148–154 (2009).
  • MacDonald FR , PeelJE, JonesHB et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes. Metab. 12 , 1004–1012 (2010).
  • Han S , HaganDL, TaylorJR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57 , 1723–1729 (2008).
  • Jurczak MJ , LeeHY, BirkenfeldAL et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function. Diabetes 60 , 890–898 (2011).
  • Komoroski B , VachharajaniN, FengY, LiL, KornhauserD, PfisterM. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with Type 2 diabetes mellitus. Clin. Pharmacol. Ther.85 , 513–519 (2009).
  • Bailey CJ , GrossJL, PietersA, BastienA, ListJF. Effect of dapagliflozin in patients with Type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet375 , 2223–2233 (2010).
  • Wilding JPH , WooV, SolerNG et al. Long-term efficacy of dapagliflozin in patients with Type 2 diabetes mellitus receiving high doses of insulin a randomized trial. Ann. Int. Med. 156 , 405–415 (2012).
  • Ehrenkranz JRL , LewisNG, KahnRC, RothJ. Phlorizin: a review. Diabetes Metab. Res. Rev.21 , 31–38 (2005).
  • Grempler R , ThomasL, EckhardtM et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14 , 83–90 (2012).
  • Chen LH , LeungPS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for Type 2 diabetes mellitus. Diabetes Obes. Metab.15(5) , 392–402 (2013).
  • Jones D . Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat. Rev. Drug Discov.10 , 645–646 (2011).
  • Sheridan C . SGLT2 inhibitors race to enter Type-2 diabetes market. Nat. Biotech.30 , 899–900 (2012).
  • Ferrannini E , RamosSJ, SalsaliA, TangW, ListJF. Dapagliflozin monotherapy in Type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Care33 , 2217–2224 (2010).
  • Hussey EK , ClarkRV, AminDM et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with Type 2 diabetes mellitus. J. Clin. Pharmacol. 50 , 623–635 (2010).
  • Wilding JPH , NorwoodP, T‘joenC, BastienA, ListJF, FiedorekFT. A study of dapagliflozin in patients with Type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care32 , 1656–1662 (2009).
  • Rosenstock J , VicoM, WeiL, SalsaliA, ListJF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with Type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care35 , 1473–1478 (2012).
  • Musso G , GambinoR, CassaderM, PaganoG. A novel approach to control hyperglycemia in Type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann. Med.44 , 375–393 (2012).
  • Liu J , LeeT, DeFronzoRA. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes61 , 2199–2204 (2012).
  • Ferrannini E , SoliniA. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat. Rev. Endocrinol.8 , 495–502 (2012).
  • Nauck MA , Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with Type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care34 , 2015–2022 (2011).
  • Zanardi TA , HanSC, JeongEJ et al. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J. Pharmacol. Exp. Ther. 343 , 489–496 (2012).
  • Zambrowicz B , FreimanJ, BrownPM et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with Type 2 diabetes in a randomized, placebo-controlled trial. Clin. Pharmacol. Ther. 92 , 158–169 (2012).
  • Zambrowicz B , DingZM, OgbaaI et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in Type 2 diabetes. Clin. Ther. 35(3) , 273–285.e7 (2013).
  • List JF , WooV, MoralesE, TangW, FiedorekFT. Sodium-glucose cotransport inhibition with dapagliflozin in Type 2 diabetes. Diabetes Care32 , 650–657 (2009).
  • Zhang L , FengY, ListJ, KasichayanulaS, PfisterM. Dapagliflozin treatment in patients with different stages of Type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes. Metab.12 , 510–516 (2010).
  • Enigk U , BreitfeldJ, SchleinitzD et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics 12 , 1119–1126 (2011).
  • Wheeler E , BarrosoI. Genome-wide association studies and Type 2 diabetes. Brief Funct. Genomics10 , 52–60 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.